962 related articles for article (PubMed ID: 15569311)
21. Stimulation of soluble guanylyl cyclase by BAY 41-2272 relaxes anococcygeus muscle: interaction with nitric oxide.
Teixeira CE; Priviero FB; Claudino MA; Baracat JS; De Nucci G; Webb RC; Antunes E
Eur J Pharmacol; 2006 Jan; 530(1-2):157-65. PubMed ID: 16371226
[TBL] [Abstract][Full Text] [Related]
22. Impact of biological gender and soluble guanylate cyclase stimulation on renal recovery after relief of unilateral ureteral obstruction.
Wang-Rosenke Y; Mika A; Khadzhynov D; Loof T; Neumayer HH; Peters H
J Urol; 2012 Jul; 188(1):316-23. PubMed ID: 22608751
[TBL] [Abstract][Full Text] [Related]
23. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of relaxation and interaction with nitric oxide of the soluble guanylate cyclase stimulator BAY 41-2272 in mouse gastric fundus and colon.
Cosyns SM; Lefebvre RA
Eur J Pharmacol; 2012 Jul; 686(1-3):104-15. PubMed ID: 22575520
[TBL] [Abstract][Full Text] [Related]
25. Nitric oxide inhibits glomerular TGF-beta signaling via SMOC-1.
Dreieicher E; Beck KF; Lazaroski S; Boosen M; Tsalastra-Greul W; Beck M; Fleming I; Schaefer L; Pfeilschifter J
J Am Soc Nephrol; 2009 Sep; 20(9):1963-74. PubMed ID: 19578009
[TBL] [Abstract][Full Text] [Related]
26. Effects of all-trans-retinoic acid (atRA) on inducible nitric oxide synthase (iNOS) activity and transforming growth factor beta-1 production in experimental anti-GBM antibody-mediated glomerulonephritis.
Datta PK; Reddy RS; Lianos EA
Inflammation; 2001 Dec; 25(6):351-9. PubMed ID: 11831438
[TBL] [Abstract][Full Text] [Related]
27. Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis.
Peters H; Border WA; Noble NA
Kidney Int; 2000 Mar; 57(3):992-1001. PubMed ID: 10720952
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.
Mullershausen F; Russwurm M; Friebe A; Koesling D
Circulation; 2004 Apr; 109(14):1711-3. PubMed ID: 15066950
[TBL] [Abstract][Full Text] [Related]
29. Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney.
Bai Y; Ye S; Mortazavi R; Campese V; Vaziri ND
Am J Physiol Renal Physiol; 2007 Mar; 292(3):F974-80. PubMed ID: 17122386
[TBL] [Abstract][Full Text] [Related]
30. Long-term administration of BAY 41-2272 prevents bladder dysfunction in nitric oxide-deficient rats.
Mónica FZ; Reges R; Cohen D; Silva FH; De Nucci G; D'Ancona CA; Antunes E
Neurourol Urodyn; 2011 Mar; 30(3):456-60. PubMed ID: 21412825
[TBL] [Abstract][Full Text] [Related]
31. Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats.
Priviero FB; Zemse SM; Teixeira CE; Webb RC
Am J Hypertens; 2009 May; 22(5):493-9. PubMed ID: 19247264
[TBL] [Abstract][Full Text] [Related]
32. Receptor-controlled phosphorylation of alpha 1 soluble guanylyl cyclase enhances nitric oxide-dependent cyclic guanosine 5'-monophosphate production in pituitary cells.
Kostic TS; Andric SA; Stojilkovic SS
Mol Endocrinol; 2004 Feb; 18(2):458-70. PubMed ID: 14630997
[TBL] [Abstract][Full Text] [Related]
33. Endurance training upregulates the nitric oxide/soluble guanylyl cyclase/cyclic guanosine 3',5'-monophosphate pathway in the striatum, midbrain and cerebellum of male rats.
Chalimoniuk M; Chrapusta SJ; Lukačova N; Langfort J
Brain Res; 2015 Aug; 1618():29-40. PubMed ID: 26006108
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effects on human eosinophil chemotaxis in vitro by BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase.
Thomazzi SM; Moreira J; De Nucci G; Antunes E
Biochem Pharmacol; 2005 Mar; 69(6):875-82. PubMed ID: 15748699
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis.
Peters H; Rückert M; Gaedeke J; Liefeldt L; Ketteler M; Sharma AM; Neumayer HH
J Hypertens; 2003 Apr; 21(4):771-80. PubMed ID: 12658024
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of NO-sensitive guanylyl cyclase subunits during the development of rat cerebellar granule cells: regulation via N-methyl-D-aspartate receptors.
Jurado S; Sanchez-Prieto J; Torres M
J Cell Sci; 2003 Aug; 116(Pt 15):3165-75. PubMed ID: 12799420
[TBL] [Abstract][Full Text] [Related]
37. The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.
Roger S; Badier-Commander C; Paysant J; Cordi A; Verbeuren TJ; Félétou M
Br J Pharmacol; 2010 Nov; 161(5):1044-58. PubMed ID: 20977455
[TBL] [Abstract][Full Text] [Related]
38. Heme oxygenase-1 overexpression fails to attenuate hypertension when the nitric oxide synthase system is not fully operative.
Polizio AH; Santa-Cruz DM; Balestrasse KB; Gironacci MM; Bertera FM; Höcht C; Taira CA; Tomaro ML; Gorzalczany SB
Pharmacology; 2011; 87(5-6):341-9. PubMed ID: 21646819
[TBL] [Abstract][Full Text] [Related]
39. Preserved activity of soluble guanylate cyclase (sGC) in iliac artery from middle-aged rats: Role of sGC modulators.
Justo AFO; de Oliveira MG; Calmasini FB; Alexandre EC; Bertollotto GM; Jacintho FF; Antunes E; Mónica FZ
Nitric Oxide; 2021 Jan; 106():9-16. PubMed ID: 33122152
[TBL] [Abstract][Full Text] [Related]
40. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
Knorr A; Hirth-Dietrich C; Alonso-Alija C; Härter M; Hahn M; Keim Y; Wunder F; Stasch JP
Arzneimittelforschung; 2008; 58(2):71-80. PubMed ID: 18412020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
